Fire ant-venom anaphylaxis prevalence in the general population and patients with systemic mastocytosis.

IF 3.3 Q2 ALLERGY
Frontiers in allergy Pub Date : 2025-03-31 eCollection Date: 2025-01-01 DOI:10.3389/falgy.2025.1570123
Jeremy C McMurray, Brandon J Schornack, Karla E Adams, Robert L McCoy, Amanda K Marshall, Janet A Brunader, Irina Maric, Dean D Metcalfe, Nathan A Boggs
{"title":"Fire ant-venom anaphylaxis prevalence in the general population and patients with systemic mastocytosis.","authors":"Jeremy C McMurray, Brandon J Schornack, Karla E Adams, Robert L McCoy, Amanda K Marshall, Janet A Brunader, Irina Maric, Dean D Metcalfe, Nathan A Boggs","doi":"10.3389/falgy.2025.1570123","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Stinging Hymenoptera can induce fatal anaphylaxis, especially in patients with systemic mastocytosis. Fire ants, <i>Solenopsis invicta</i> and <i>S. richteri,</i> from South America have recently colonized three continents. Prevalence of fire ant-venom anaphylaxis in the general population and in systemic mastocytosis is unknown. The aim was to determine fire ant-venom anaphylaxis prevalence among Tricare beneficiaries and those with systemic mastocytosis.</p><p><strong>Methods: </strong>We queried the beneficiary immunotherapy prescription database for patients who received immunotherapy with Hymenoptera venom or fire ant whole-body extract and the Tricare beneficiary population health registry database for patients with an ICD-10 code for Hymenoptera venom allergy (HVA). Greater than 95% of the beneficiary population were patients living in the United States. Chart review of a random sample of 150 patients linked to a HVA ICD-10 code was performed to determine the percent of patients with Hymenoptera-venom anaphylaxis. Retrospective review of a systemic mastocytosis cohort was performed to assess fire ant-venom anaphylaxis rate and treatment patterns.</p><p><strong>Results: </strong>Fire ant immunotherapy was the most frequently ordered individual immunotherapy prescription 45.9% (<i>n</i> = 878). Fire ant prescriptions surpassed all flying Hymenoptera immunotherapy prescriptions combined in six states. Fire ant and flying Hymenoptera-venom anaphylaxis prevalence in the general population was 0.048% and 0.083%, respectively. Fire ant-venom anaphylaxis prevalence in the 14 colonized states was 0.085%. More patients with systemic mastocytosis had anaphylaxis triggered by fire ant than all flying Hymenoptera combined.</p><p><strong>Conclusion: </strong>Fire ant-venom anaphylaxis prevalence in the general population and patients with systemic mastocytosis is higher than all flying Hymenoptera-venom anaphylaxis combined in colonized states. Fire ant-venom anaphylaxis in systemic mastocytosis is frequently misdiagnosed and not treated with epinephrine.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1570123"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994729/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/falgy.2025.1570123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Stinging Hymenoptera can induce fatal anaphylaxis, especially in patients with systemic mastocytosis. Fire ants, Solenopsis invicta and S. richteri, from South America have recently colonized three continents. Prevalence of fire ant-venom anaphylaxis in the general population and in systemic mastocytosis is unknown. The aim was to determine fire ant-venom anaphylaxis prevalence among Tricare beneficiaries and those with systemic mastocytosis.

Methods: We queried the beneficiary immunotherapy prescription database for patients who received immunotherapy with Hymenoptera venom or fire ant whole-body extract and the Tricare beneficiary population health registry database for patients with an ICD-10 code for Hymenoptera venom allergy (HVA). Greater than 95% of the beneficiary population were patients living in the United States. Chart review of a random sample of 150 patients linked to a HVA ICD-10 code was performed to determine the percent of patients with Hymenoptera-venom anaphylaxis. Retrospective review of a systemic mastocytosis cohort was performed to assess fire ant-venom anaphylaxis rate and treatment patterns.

Results: Fire ant immunotherapy was the most frequently ordered individual immunotherapy prescription 45.9% (n = 878). Fire ant prescriptions surpassed all flying Hymenoptera immunotherapy prescriptions combined in six states. Fire ant and flying Hymenoptera-venom anaphylaxis prevalence in the general population was 0.048% and 0.083%, respectively. Fire ant-venom anaphylaxis prevalence in the 14 colonized states was 0.085%. More patients with systemic mastocytosis had anaphylaxis triggered by fire ant than all flying Hymenoptera combined.

Conclusion: Fire ant-venom anaphylaxis prevalence in the general population and patients with systemic mastocytosis is higher than all flying Hymenoptera-venom anaphylaxis combined in colonized states. Fire ant-venom anaphylaxis in systemic mastocytosis is frequently misdiagnosed and not treated with epinephrine.

普通人群和全身性肥大细胞增多症患者的抗毒液过敏反应患病率。
背景:蜇伤膜翅目昆虫可引起致死性过敏反应,特别是对全身肥大细胞增多症患者。来自南美洲的火蚁(Solenopsis invicta)和李氏火蚁(s.r ichteri)最近在三大洲殖民。一般人群和全身性肥大细胞增多症中抗毒液过敏反应的患病率尚不清楚。目的是确定抗毒液过敏反应在Tricare受益人和系统性肥大细胞增多症患者中的患病率。方法:我们查询了接受膜翅目毒液或火蚁全身提取物免疫治疗患者的受益免疫治疗处方数据库,以及Tricare受益人群健康登记数据库中膜翅目毒液过敏(HVA)的ICD-10编码患者。超过95%的受益人群是生活在美国的患者。对与HVA ICD-10代码相关的150例随机样本进行图表审查,以确定膜翅虫毒液过敏反应患者的百分比。对系统性肥大细胞增多症队列进行回顾性回顾,以评估五种抗毒液过敏反应率和治疗模式。结果:火蚁免疫治疗是最常用的个体免疫治疗处方(45.9%)(n = 878)。在六个州,火蚁的处方超过了所有飞行膜翅目免疫疗法处方的总和。普通人群中火蚁和飞膜翅目毒液过敏反应患病率分别为0.048%和0.083%。14个殖民地的5种抗毒液过敏反应患病率为0.085%。全身性肥大细胞增多症患者发生火蚁引起的过敏反应的比例高于所有飞行膜翅目昆虫的总和。结论:在蜂定国,普通人群和全身肥大细胞增多症患者的火焰抗毒液过敏反应患病率高于所有飞行膜翅目毒液过敏反应的总和。全身肥大细胞增多症的抗毒液过敏反应常被误诊,不能用肾上腺素治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信